ADC restructures debt as Zynlonta struggles to make an impact

Deerfield Management is to take a stake in Swiss-based ADC Therapeutics (NYSE:ADCT), a Lausanne-based antibody-drug conjugate company, as the company restructures its bonds.

ADC closed a new $175 million senior secured term loan with a division of Blue Owl Capital and with funds from Oaktree Capital Management.

Meanwhile, a $115 million debt with Deerfield has been settled in full, through an agreement that includes a…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

About Sharon Joseph

Check Also

Todd Minerals Ltd. announces conversion of Northcliff Resources loan

Get instant alerts when news breaks on your stocks. Claim your one week free trial …